In a recently published retrospective study by Nasser et al., GLP-1RA users undergoing EGD were identified and matched to non-users undergoing EGD
and oral semaglutide)
Report Scope and Analytical Framing Concise View of Market Direction Market Size, Growth and Scenario Framing Commercial and Technical Scope How the Market Splits Into Decision-Relevant Buckets Where Demand Comes From and How It Behaves Supply Footprint, Trade and Value Capture Trade Flows and External Dependence Price Formation and Revenue Logic Who Wins and Why Where Growth and Supply Concentrate Commercial Entry and Scaling Priorities Where the Best Expansion Logic Sits Leading Players and Strategic Archetypes Detailed View of the Most Important National Markets How the Report Was Built Dominant market share in GLP-1 diabetes segment Strong competitor with dual GIP/GLP-1 agonist Early market entrant, now faces competition Markets GLP-1 in certain regions Product withdrawn in 2017-2018 Previously marketed exenatide, pipeline interest Key player in Chinese market Significant Chinese generic manufacturer Developing next-gen GLP-1/GCGR candidate GLP-1 involvement via partnerships/combinations Indirect via DPP-4 combos, pipeline interest Develops next-gen peptides, partners with Boehringer Developed long-acting GLP-1 candidate Exploring GLP-1 delivery via inhaled tech Limited direct role, potential via Sandoz generics Potential future biosimilar entrant Potential future biosimilar entrant Potential future biosimilar entrant Potential future biosimilar entrant Potential future biosimilar entrant Instant access
Side Effects: Are They the Same
But, doctors need to think about each patients situation before prescribing it
After extensive diagnostic workup, the most likely etiology of her clinical presentation was favored to be non-alcoholic Wernickes encephalopathy (NAWE) and treatment-induced neuropathy of diabetes (TIND)
